A Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1
| Status: | Recruiting |
|---|---|
| Conditions: | HIV / AIDS |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/30/2013 |
| Start Date: | July 2009 |
| End Date: | August 2017 |
| Contact: | Pfizer CT.gov Call Center |
| Phone: | 1-800-718-1021 |
A Phase 2b Open-Label Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1 Infected Subjects
The purpose of the protocol is to assess long-term safety and tolerability of subjects who
discontinue for any reason from UK-453,061 qualifying studies.
To assess long term safety and tolerability of subjects who discontinue for any reason from
UK-453,061 studies. The study will also assess efficacy of the subsequent regimens in these
patients.
Inclusion Criteria:
- Previous participation in a qualifying study.
- Male or female at least 18 years of age available for a follow-up period of at least
96 weeks.
Exclusion Criteria:
- Concurrent treatment in another clinical trial.
- Unwilling or unable to be followed for 12 months
We found this trial at
5
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials